New progress in hydrogen-synergistic diagnostic and therapeutic nanoplatforms for tumor treatment.
Hydrogen synergistic therapy, an emerging and promising strategy in tumor treatment, has been bolstered by nanotechnology to establish a stable and multifunctional foundation for its implementation.
APA
Shi M, Duan Y, et al. (2026). New progress in hydrogen-synergistic diagnostic and therapeutic nanoplatforms for tumor treatment.. Biomaterials science, 14(5), 1180-1205. https://doi.org/10.1039/d5bm01802a
MLA
Shi M, et al.. "New progress in hydrogen-synergistic diagnostic and therapeutic nanoplatforms for tumor treatment.." Biomaterials science, vol. 14, no. 5, 2026, pp. 1180-1205.
PMID
41641928
Abstract
Hydrogen synergistic therapy, an emerging and promising strategy in tumor treatment, has been bolstered by nanotechnology to establish a stable and multifunctional foundation for its implementation. Hydrogen-synergistic diagnostic and therapeutic nanoplatforms (HSDT-NPs), a novel type of tool for tumor treatment, integrate hydrogen therapy with various tumor diagnostic and therapeutic strategies, significantly enhancing the efficiency and specificity of tumor treatment, which is crucial for achieving precision therapy at the tumor site. The construction of HSDT-NPs relies on the design of hydrogen nanomaterials and the selection and assembly of synergistic units. Through HSDT-NPs, the synergistic effects between hydrogen therapy and other strategies are markedly enhanced, not only improving the efficacy of traditional therapies on tumors but also effectively protecting normal cells. Based on different material types, this study explores the construction strategies of HSDT-NPs. Subsequently, focusing on the collaborative treatment modes, it delves into the synergistic mechanisms of HSDT-NPs. Our work aims to offer new perspectives and innovative approaches for advancing cancer treatment based on hydrogen therapy research.
MeSH Terms
Hydrogen; Humans; Neoplasms; Animals; Antineoplastic Agents; Nanoparticles
같은 제1저자의 인용 많은 논문 (5)
- Enhanced therapeutic efficacy of sequential ¹⁷⁷Lu/²²⁵Ac-LNC1004 FAP-targeted radionuclide therapy combined with anti-PD-L1 blockade in pancreatic cancer.
- Celastrol inhibits the immune escape and proliferation of triple - negative breast cancer (TNBC) through the LKB1 - AMPK - PD-L1/MYC signaling pathway.
- Transcriptomic landscape of transposable elements reveals - as a potential oncogene and therapeutic target in pancreatic adenocarcinoma.
- Accelerating discovery of cancer causes for prevention in the era of rising early-onset cancers.
- Latent profile analysis of uncertainty in illness and eating self-efficacy in patients with gastric cancer and its associated factors: a cross-sectional study.